We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
RIDAURA auranofin 3mg capsules (Canada)
Section 19A approved medicine
RIDAURA auranofin 3mg capsules (Canada)
Section 19A approval holder
Boucher & Muir Pty Ltd T/A Advanz Pharma ABN 58 000 140 474
Phone
02 9431 6333
Approved until
Status
Current
Medicines in short supply/unavailable
RIDAURA auranofin 3mg tablet bottle - ARTG 13000
Indication(s)
Adjunctive treatment of active classical or definite rheumatoid arthritis in adults who have an insufficient therapeutic response to, or are intolerant of, an adequate trial of a baseline therapeutic program, including among other measures, full doses of one or more non-steroidal anti-inflammatory drugs. RIDAURA is not indicated in non-rheumatoid arthropathies such as osteoarthrosis. RIDAURA should be added to a comprehensive baseline therapeutic program.
Additional information
Images
